These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8668657)

  • 1. Determination intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans.
    Sinko PJ; Hu P
    Pharm Res; 1996 Jan; 13(1):108-13. PubMed ID: 8668657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of carrier-mediated transport of 2',3'-dideoxypurine nucleosides in the rat ileum using a bidirectional perfusion technique.
    DeGraw RT; Anderson BD
    Pharm Res; 2004 Feb; 21(2):300-8. PubMed ID: 15032312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2',3'-dideoxyinosine in the mesenteric vein cannulated rat ileum.
    Singhal D; Ho NF; Anderson BD
    J Pharm Sci; 1998 May; 87(5):569-77. PubMed ID: 9572907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral absorption of anti-aids nucleoside analogues: 3. Regional absorption and in vivo permeability of 2',3'-dideoxyinosine in an intestinal-vascular access port (IVAP) dog model.
    Sinko PJ; Sutyak JP; Leesman GD; Hu P; Makhey VD; Yu H; Smith CL
    Biopharm Drug Dispos; 1997 Nov; 18(8):697-710. PubMed ID: 9373726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats.
    Hasegawa T; Juni K; Saneyoshi M; Kawaguchi T
    Biol Pharm Bull; 1996 Apr; 19(4):599-603. PubMed ID: 8860966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.
    Cao X; Gibbs ST; Fang L; Miller HA; Landowski CP; Shin HC; Lennernas H; Zhong Y; Amidon GL; Yu LX; Sun D
    Pharm Res; 2006 Aug; 23(8):1675-86. PubMed ID: 16841194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats.
    Anderson BD; Morgan ME; Singhal D
    Pharm Res; 1995 Aug; 12(8):1126-33. PubMed ID: 7494823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms.
    Dahlgren D; Roos C; Johansson P; Lundqvist A; Tannergren C; Abrahamsson B; Sjögren E; Lennernäs H
    Mol Pharm; 2016 Sep; 13(9):3022-33. PubMed ID: 27500599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the intestinal absorption and bioavailability of γ-tocotrienol and α-tocopherol: in vitro, in situ and in vivo studies.
    Abuasal BS; Qosa H; Sylvester PW; Kaddoumi A
    Biopharm Drug Dispos; 2012 Jul; 33(5):246-56. PubMed ID: 22528033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations.
    Sinko PJ; Hu P; Waclawski AP; Patel NR
    J Pharm Sci; 1995 Aug; 84(8):959-65. PubMed ID: 7500281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices.
    Westerhout J; van de Steeg E; Grossouw D; Zeijdner EE; Krul CA; Verwei M; Wortelboer HM
    Eur J Pharm Sci; 2014 Oct; 63():167-77. PubMed ID: 25046168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive and carrier-mediated intestinal absorption components of captopril.
    Hu M; Amidon GL
    J Pharm Sci; 1988 Dec; 77(12):1007-11. PubMed ID: 3072405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
    Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
    Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
    J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.